<DOC>
	<DOCNO>NCT02663479</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety proprietary nutraceutical supplement capsule form 4 month treat blood pressure group chronic hypertensive subject receive pharmaceutical anti-hypertensive agent nutraceutical supplement .</brief_summary>
	<brief_title>Nutraceutical Supplement Management Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Inclusion Criteria Diagnosed chronic hypertension : Blood pressure study entry must great equal systolic blood pressure 140 mm Hg le 180 mm Hg diastolic blood pressure great equal 90 mm Hg le 105 mm Hg Subjects take prescription antihypertensive drug . Subjects must nutraceutical supplement least 30 day prior entry study . Exclusion Criteria Myocardial infarction , PTCA , stent , CABG within 5 year , know clinical CHD clinical angina . History cerebrovascular accident ( CVA ) . Creatinine 2.5 mg/dL . Known allergy sensitivity component study blood pressure supplement . Chronic liver disease AST , ALT , alkaline phosphatase 1.5 x normal lab value . Known cancer within 2 year . Clinical congestive heart failure ( systolic diastolic CHF ) Pregnant nurse woman woman . Women child bearing age approve contraception control . Type 1 Type 2 diabetes mellitus medication . If study subject develop BP 180 mm Hg systolic 110 mm Hg diastolic study , discontinue study investigator immediately start rescue drug therapy BP control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>